免疫原性细胞死亡（ICD）引发的适应性免疫应答有助于抗癌治疗。然而，ICD相关基因（ICDAGs）在临床应用中以及对肿瘤微环境（TME）的潜在影响尚不清楚。使用共识聚类方法将TCGA队列分为不同的ICD聚类，并评估了各个ICD聚类的临床结果和TME特征。GSVA用于量化重要基因集的激活情况。为了建立与ICD分子亚型相关的预后模型（ICDRPM），我们对ICD亚型间差异表达基因（DEGs）进行了LASSO Cox回归分析。通过分析免疫细胞比例、TME、基因组突变差异、免疫疗法的疗效和药物敏感性来评估风险组的评估。为了增强ICDRPM的临床有效性，我们开发了一种图解。我们鉴定出两种不同的分子亚型，ICDRGs的变化与患者的临床结果和TME特征相关。从两个ICD聚类中获得了1162个差异表达基因（DEGs），随后开发了ICDRPS来预测总生存期（OS）。在内部和外部验证期间，被分类为高风险的患者显示出明显较差的总生存期，与被分类为低风险的患者相比。此外，ICDRPS（ICD_score）被确定为BC患者的独立预后指标，表现出优秀的预测性能。然后，我们构建了一个可靠的图解，以提高ICD_score的实用性。此外，低风险个体显示出更强的免疫细胞浸润，更高的免疫检查点表达和更高的IPS-PD-1综合IPS-CTLA4分数，表明对免疫检查点抑制剂（ICIs）的反应更强。此外，被分类为低风险或高风险的个体对抗癌药物的敏感性相反。ICD相关基因模型的构建为免疫疗法提供了有意义的临床意义，并为BC患者的个体化治疗提供了方便。© 2023作者。

Immunogenic cell death (ICD) triggers adaptive immune responses that aid in anticancer therapy. However, the significance of ICD-associated genes (ICDAGs) in clinical applications and their potential impact on the tumor microenvironment (TME) remains unclear.The TCGA cohort was divided into different ICD clusters using the method of Consensus clustering. We assessed the clinical results and TME features of various ICD clusters. GSVA quantified the activation of hallmark gene sets. To establish an ICD molecular subtypes-related prognostic model (ICDRPM), we performed LASSO Cox regression analysis on the differentially expressed genes (DEGs) among ICD subtypes. We evaluated the assessment of risk groups by analyzing the proportion of immune cells, the TME, differences in genomic mutation, the efficacy of immunotherapy, and drug sensitivity. To enhance the clinical effectiveness of the ICDRPM, a nomograph was developed.Two distinct molecular subtypes were identified, and changes in ICDRGs were associated with clinical outcomes and TME characteristics of patients. A total of 1162 differentially expressed genes (DEGs) were obtained from two ICD clusters, and an ICDRPS was then developed to predict overall survival (OS). During both internal and external validation, patients classified as high-risk exhibited significantly poorer overall survival compared to those classified as low-risk. Additionally, the ICDRPS (ICD_score) was identified as an independent prognostic indicator for patients with BC, demonstrating excellent predictive performance. Afterward, we constructed a dependable nomogram to improve the practicality of the ICD_score. Furthermore, low-risk individuals showed stronger immunocyte infiltration, higher immune checkpoint expression, and higher IPS-PD-1 combined IPS-CTLA4 scores, indicating a greater response to immune checkpoint inhibitors (ICIs). Moreover, individuals categorized as having low or high risk exhibited contrasting sensitivity to anticancer medications.The model constructed for genes related to ICD provided meaningful clinical implications for immunotherapy, and facilitated individualized treatment for BC patients.© 2023 The Authors.